Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

File(s)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.pdf (885.64 KB)

Published version

Show more

Author(s)

Nathan, SD

Albera, C

Bradford, WZ

Costabel, U

du Bois, RM

more

Type

Journal Article

Date Issued

2016-04-14

Date Acceptance

2016-02-13

Citation

THORAX, 2016, 71 (5), pp.429-435

URI

http://hdl.handle.net/10044/1/50741

DOI

https://www.dx.doi.org/10.1136/thoraxjnl-2015-207011

ISSN

0040-6376

Publisher

BMJ PUBLISHING GROUP

Start Page

429

End Page

435

Journal / Book Title

THORAX

Volume

71

Issue

5

Copyright Statement

This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/

Identifier

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000375075000009&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Subjects

Science & Technology

Life Sciences & Biomedicine

Respiratory System

INTERSTITIAL PNEUMONIA

MANAGEMENT

SURVIVAL

Publication Status

Published